German Pharma Fears Drug Prescribing Report Will Be Used To Force Down Prices Again
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug makers in Germany say this year’s widely-referenced Pharmaceutical Prescribing Report contains misleading data and warn it will be used to suppress prices even further, stifling innovation and restricting patient access to drugs.
You may also be interested in...
German Drug Report Could Mean More Pressure On Pharma Revenues
The annual German prescription report suggests an additional €4.6 billion can be cut from the country’s annual drug expenditures, which could cause the government to extend its temporary price moratorium and mandatory rebate, as well as pursue other cost-cutting measures.
Reversal Of Fortune For German Pharma As Bundesrat Supports Enhanced Drug Price Transparency
Germany’s upper house of parliament, the Bundesrat, has decided after considerable wrangling that negotiated and discounted reimbursement prices of drugs sold in Europe’s biggest market will be made public, virtually ensuring that further price erosion will spread across the region.
Success Of German Cost-Control Law Raises Prospect Of Further Cuts For Pharma
Germany's 2011 pharmaceutical prescribing report shows that the cost control law (AMNOG) is fulfilling its purpose, prompting insurers to call for even further pressure on the industry to reduce costs.